Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04300179

Enrollment

Registered

2020-03-09

Start date

2020-07-07

Completion date

2020-12-16

Last updated

2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Neoplasms, Neoplasms, Soft Tissue Neoplasms

Keywords

Ewing's sarcoma (ES), Peripheral primitive neuroectodermal tumor (PNET)

Brief summary

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) & treatment outcomes in these patients.

Detailed description

Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET), Both entities that currently comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), were originally described as distinct clinicopathologic entities. Primitive neuroectodermal tumors (PNETs) first described in 1918 by Stout as a malignant tumor arising from major nerve. Later, in 1921, ES was described as an undifferentiated tumor involving the diaphysis of long bones. It was also reported to arise in soft tissue (extraosseous ES). EFT is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 19 Years

Healthy volunteers

Inclusion criteria

* Patients whose age less than 19 years. Patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT).

Exclusion criteria

* Patients whose age more than 19 years. Patients diagnosed with other bone & soft tissue neoplasms.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	From date of treatment initiation until the date of death from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months	Participants will be retrospectively followed forward in time from the date of initiation of treatment till death from any cause, an expected average of 5 years
Event Free Survival (EFS)	From date of treatment initiation until the date of event from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months	Participants will be retrospectively followed forward in time from the date of initiation of treatment till occurrence of an event from any cause (tumor progression, relapse) or death, an expected average of 5 years

Countries

Egypt

Outcome results